Please assess the completion status of the following clinical trial:

Trial Title: Cyclophosphamide Therapy for Refractory Antibody-Mediated Rejection (AMR) in Kidney Transplants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a living or deceased donor kidney transplant~* Failed current standard of care for late antibody-mediated rejection~* Persistent de novo donor specific antibody and a concurrent biopsy with histologic evidence of acute antibody-mediated inflammation~* Adults with reproductive potential must agree to use approved methods of birth control while in the study~Exclusion Criteria:~* Leukopenia (WBC) \< 3.0 x 109/L~* Creatinine Clearance less than or equal to 25 ml/min/1.73m2~* HCV or HBV positive~* BKV or CMV viremia assessed by PCR~* Any active infection~* Use of other investigational drugs within 4 weeks of study~* Pregnancy/breast feeding/unwilling or unable to take birth control~* Active malignancy~* de novo DSA occurring equal to or greater than15 years after kidney transplant~* Screening biopsy with equal to or greater than cg2 on Banff criteria~* Cumulative/lifetime dose of cyclophosphamide, including anticipated total study dose (calculated according to Creatinine Clearance and mg/kg/day) equal to or greater than 36 g.~* Any condition that, in the opinion of the investigator, would pose risk to the subject's safe participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide (Type: EXPERIMENTAL): Cyclophosphamide 1.5 mg/kg orally daily for 180 days (26 weeks) adjusted for renal function.

Based on this trial design, predict the completion outcome and termination type (if applicable).